The compound (Scheme I) belongs to a series of cyano-pyridinones that have been evaluated for their anticancer properties (Rostom et al., 2011). The tetrahydrobenzo[h]quinoline fused-ring system is buckled owing to the ethylene -CH 2 CH 2fragment, the benzene ring and the pyridine ring being twisted by 19.7 (1)°. The 4-subsituted aromatic ring is bent away from the pyridine ring by 50.3 (1) ° in order to avoid crowding the cyanide substituent ( Fig. 1) . Two molecules are linked by an N-H···O hydrogen bonds to form a centrosymmetric dimer (Table 1) .
In the molecule of the title compound, C 21 H 16 N 2 O 2 , the tetrahydrobenzo[h]quinoline fused-ring system is buckled owing to the ethylene -CH 2 CH 2 -fragment, the benzene ring and the pyridine ring being twisted by 19.7 (1) . The 4-substituted aromatic ring is bent away from the pyridine ring by 50.3 (1) in order to avoid crowding the cyanide substituent. In the crystal, two molecules are linked by a pair of N-HÁ Á ÁO hydrogen bonds to form a centrosymmetric dimer.
Related literature
For background to the anticancer properties of this class of compounds, see: Rostom et al. (2011) . Table 1 Hydrogen-bond geometry (Å , ).
Experimental
Symmetry code: (i) Àx þ 1; Ày þ 1; Àz þ 1.
Data collection: CrysAlis PRO (Agilent, 2010); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: X-SEED (Barbour, 2001); software used to prepare material for publication: publCIF (Westrip, 2010). (7) 0.62548 (7) 0.10368 (13) 0.0151 (2) C11 0.24237 (7) 0.60637 (7) 0.21242 (13) 0.0150 (2) C12 0.26806 (7) 0.55905 (7) 0.36226 (13) 0.0149 (2) C13 0.36372 (7) 0.52863 (7) 0.40914 (13) 0.0151 (2) C14 0.20310 (7) 0.54250 (7) 0.48475 (13) 0.0159 (2) C15 0.14293 (7) 0.63712 (7) C18-O2-C21 117.24 (9) C1-C10-C11 119.10 (9) C1-N1-C13 124.74 (9) C1-C10-C9 118.18 (10) 
